Investors

Financials & Filings

Filing date Form Description Filing Group View
DFAN14A

Additional proxy soliciting materials filed by non-management

Proxy Filings
SC 13D/A

An amendment to a SC 13D filing

Other
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
SC 13G/A

An amendment to the SC 13G filing

Other
SC 13G/A

An amendment to the SC 13G filing

Other

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.